BioXcel Therapeutics (BTAI) EBIT (2017 - 2026)

BioXcel Therapeutics has reported EBIT for 10 years, with the latest figure at -$10.2 million in Q2 2026.

• On a quarterly basis, EBIT rose 35.7% year-over-year to -$10.2 million in Q2 2026; TTM through Jun 2026 was -$44.9 million, a 13.16% increase from a year earlier, with the FY2025 full-year figure at -$50.5 million, up 24.96% from the prior year.
• EBIT was -$10.2 million for Q2 2026 at BioXcel Therapeutics, roughly flat from -$10.2 million in the prior quarter.
• The five-year high for EBIT was -$10.1 million in Q1 2025, with the low at -$52.9 million in Q4 2022.
• Average EBIT over 5 years is -$26.1 million, with a median of -$18.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: EBIT tumbled 102.42% in 2022, then soared 68.34% in 2024.
• Over 5 years, EBIT stood at -$52.9 million in 2022, then surged by 62.42% to -$19.9 million in 2023, then jumped by 47.21% to -$10.5 million in 2024, then grew by 2.01% to -$10.3 million in 2025, then advanced by 0.87% to -$10.2 million in 2026.
• The last three EBIT figures came in at -$10.2 million (Q2 2026), -$10.2 million (Q1 2026), and -$10.3 million (Q4 2025), per Business Quant data.